30 closest matches · ranked by relevance
Melanoma · Metastases
Primary: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone — 9.95…
Stage III Melanoma · Stage IV Melanoma · Unresectable Melanoma
Primary: Percentage of Participants With Progression-free Survival at 6 Months — 68 percentage of participants
Melanoma
Primary: Progression Free Survival (PFS) — 122; 125 days — p=0.492
Unresectable Malignant Neoplasm · Melanoma · Metastatic Melanoma
Primary: Resectability Rate — 8; 2 Participants
Recurrent Melanoma · Stage III Skin Melanoma · Stage IV Skin Melanoma
Primary: Response — 11 participants
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Metastatic Melanoma
Primary: Objective Response Rate (ORR) — 1; 1 Participants
Melanoma
Primary: Overall Survival (OS) — 11.17; 9.07 Months — p=0.0009
Melanoma (Skin)
Primary: Rate of 6 Month Progression-Free Survival — 18; 15; 4; 12 Participants
Cancer · Melanoma
Primary: Progression Free Survival (PFS) — 148; 82 days — p=0.068
Advanced Melanoma · Unresectable Melanoma
Primary: Overall Response Rate (ORR) — 10 percentage of patients
Melanoma
Primary: Response to Neoadjuvant Therapy by Therapy Arms: Clinical Response Rates (CR + PR + SD) — 4; 7; 14; 11 Participants
Metastatic Melanoma
Primary: Immune Response Rate — 0.29; 0.67 proportion of participants
Metastatic or Unresectable Cutaneous Melanoma
Primary: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 — 2.83; 1.51 Months — p=< 0.001
Metastatic Melanoma · Mucosal Melanoma · Stage IV Cutaneous Melanoma AJCC v6 and v7
Primary: Progression-free Survival (PFS) — 139; 94 days
Melanoma (Skin)
Primary: Progression-free Survival at 6 Months — 32.8; 56.1 % of patients alive and progression free
Melanoma
Primary: Overall Survival (OS) — NA; 10.84 Months — p=<0.0001
Ciliary Body and Choroid Melanoma, Medium/Large Size · Extraocular Extension Melanoma · Iris Melanoma
Primary: Objective Response Rate Assessed by Response Evaluation Criteria for Solid Tumors (RECIST) — 2 participants
Metastatic Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Overall Response Rate, Defined Per RECIST 1.1 — 1; 5; 11; 16 Participants
Recurrent Melanoma · Stage IIIA Melanoma · Stage IIIB Melanoma
Primary: Best Overall Response Rate (BORR) — 2; 17; 1 Participants
Metastatic Melanoma
Primary: 6-Month Progression-Free Survival (PFS) Rate — 29 participants
Malignant Melanoma
Primary: Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) — 18.92 percentage of…
Mucosal Lentiginous Melanoma · Acral Melanoma · Melanoma
Primary: 4-month Progression-Free Survival Rate — 0.27; 0.125 proportion of patients
Malignant Melanoma
Primary: Best Overall Response (BOR) Assessed by an Independent Review Committee Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) — 52.3 Percentage of participants
Melanoma
Primary: Clinical Responses in Patients With Metastatic Ocular Melanoma — 0; 0; 9; 7 Participants
Malignant Melanoma
Primary: Number of Participants With Any Adverse Event, Adverse Events With Severity, Adverse Events Leading to Discontinuation — 346; 115; 15; 7 participants
Melanoma (Skin)
Primary: 9-week Progression-free Survival Rate — 0.44 proportion of patients
Melanoma
Primary: Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review…
Malignant Melanoma
Primary: Best Overall Response Rate (BORR) Within Brain of Previously Untreated Participants (Assessed by Independent Review Committee [IRC] Using Modified Response Evaluation…
Melanoma
Primary: Overall Response Rate (ORR) — 10 Percentage of Participants